2021-006543-10: Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Estudio de XB002 en sujetos con tumores sólidos (JEWEL-101) |
|
|
| Not yet recruiting | 1/2 | 451 | Europe | XB002, Nivolumab, XB002, BMS-936558, Solution for infusion, Solution for injection, Opdivo | Exelixis, Inc., Exelixis, Inc. | Advanced solid tumors for whom life-prolonging therapies do not exist or available therapies are intolerable or no longer effective. Single-agent XB002 will be evaluated up to 10 tumor types, and combination treatment will also be evaluated with nivolumab in NSCLC, SCCHN, and esophageal SCC. Tumores sólidos avanzados para los que no existen terapias que prolonguen la vida o las terapias disponibles son intolerables o ya no son eficaces. El agente único XB002 se evaluará hasta en 10 tipos de tumores, y también se evaluará el tratamiento combinado con nivolumab en el CPNM, el SCCHN y el CCE de esófago., SUBJECTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS SUJETOS CON TUMORES SÓLIDOS LOCALMENTE AVANZADOS O METASTÁSICOS INOPERABLES, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 1 | 573 | Europe, US, RoW | XB002, Nivolumab | Exelixis, Exelixis, Inc. | Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors | 06/24 | 10/24 | | |